Axiom Investors’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Axiom Investors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,173,807	Closed	-$33.4M	–	151
2025 Q1	$33.4M	Buy	+2,173,807	New	+$38.8M	0.32%	47
2016 Q3	–	Sell	-624,750	Closed	-$31.4M	–	160
2016 Q2	$31.4M	Sell	624,750 -551,009	-47%	-$29.3M	0.91%	42
2016 Q1	$62.9M	Sell	1,175,759 -382,479	-25%	-$22.4M	1.96%	16
2015 Q4	$102M	Sell	1,558,238 -376,969	-19%	-$23.3M	3.3%	5
2015 Q3	$109M	Buy	1,935,207 +443,614	+30%	+$28.8M	3.45%	6
2015 Q2	$88.2M	Sell	1,491,593 -55,345	-4%	-$3.41M	2.53%	11
2015 Q1	$96.4M	Buy	1,546,938 +882,205	+133%	+$51.3M	2.61%	8
2014 Q4	$38.2M	Buy	+664,733	New	+$37M	0.94%	47

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Axiom Investors's TEVA Position: Q2 2025 in Review

Axiom Investors sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2025, closing a stake of 2,173,807 shares — an estimated $33.4M sold.

Axiom Investors first reported a position in TEVA in Q4 2014 and held it in 8 quarters. The position peaked at $109M in Q3 2015. 542 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

Axiom Investors reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2025 after selling out during the quarter.
Axiom Investors sold 2,173,807 Teva Pharmaceutical Industries Limited shares in Q2 2025, an estimated $33.4M.
Axiom Investors first reported a position in Teva Pharmaceutical Industries Limited in Q4 2014 and held it in 8 quarters.
Axiom Investors's Teva Pharmaceutical Industries Limited position peaked at $109M in Q3 2015.
542 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2025.

Based on Axiom Investors's 13F filing for Q2 2025, filed 7 Aug 2025.